Tuhura Biosciences, INC./NV (HURA) — SEC Filings

Q: What are the key financial highlights for Tuhura Biosciences, INC./NV?

Key financial highlights for Tuhura Biosciences, INC./NV are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Tuhura Biosciences, INC./NV?

Key executives at Tuhura Biosciences, INC./NV are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Tuhura Biosciences, INC./NV stock?

Risk factors for Tuhura Biosciences, INC./NV (HURA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Tuhura Biosciences, INC./NV?

Forward-looking statements and predictions from Tuhura Biosciences, INC./NV are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Tuhura Biosciences, INC./NV. Recent 8-K filing on Apr 22, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Tuhura Biosciences, INC./NV on SEC EDGAR

Overview

Tuhura Biosciences, INC./NV (HURA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 22, 2026: TuHURA Biosciences, Inc./NV filed an 8-K on April 22, 2026, reporting the entry into a material definitive agreement and the creation of a direct financial obligation. The filing also disclosed unregistered sales of equity securities and included Regulation FD disclosures. Specific details regarding

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 48 neutral, 2 mixed. The dominant filing sentiment for Tuhura Biosciences, INC./NV is neutral.

Filing Type Overview

Tuhura Biosciences, INC./NV (HURA) has filed 40 8-K, 1 424B5, 1 S-1/A, 3 10-Q, 2 8-K/A, 2 10-K, 1 SC 13D with the SEC between Jul 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

TuHURA Biosciences Files 8-K: Material Agreement & Financial Obligation — 8-K · Apr 22, 2026 Risk: medium
TuHURA Biosciences, Inc./NV filed an 8-K on April 22, 2026, reporting the entry into a material definitive agreement and the creation of a direct financial obli
424B5 Filing — 424B5 · Apr 8, 2026
TuHURA Biosciences Files 8-K: Officer Changes & Other Events — 8-K · Apr 8, 2026 Risk: medium
TuHURA Biosciences, Inc./NV filed an 8-K on April 8, 2026, reporting on the departure of a director or officer, other events, and financial statements/exhibits.
TuHURA Biosciences Files 8-K on Financials — 8-K · Apr 1, 2026 Risk: low
TuHURA Biosciences, Inc./NV filed an 8-K on April 1, 2026, reporting results of operations and financial condition. The filing includes financial statements and
TuHURA Biosciences Files 8-K — 8-K · Dec 10, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on December 10, 2025, reporting the entry into a material definitive agreement and o
TuHURA Biosciences Enters Material Definitive Agreement — 8-K · Dec 5, 2025 Risk: medium
On December 2, 2025, TuHURA Biosciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known
TuHURA Biosciences Files 8-K — 8-K · Nov 25, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on November 25, 2025, reporting a Regulation FD Disclosure. The company, incorporate
TuHURA Biosciences Files 8-K — 8-K · Nov 18, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on November 18, 2025, reporting other events and financial statements. The company, formerly known as Kintara Therapeutics
TuHURA Biosciences Files 8-K on Financials — 8-K · Nov 14, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on November 14, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and
TuHURA Biosciences Files 8-K for Material Agreement — 8-K · Nov 4, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on November 4, 2025, reporting a material definitive agreement entered into on Novem
8-K Filing — 8-K · Nov 3, 2025
TuHURA Biosciences Enters Material Definitive Agreement — 8-K · Oct 31, 2025 Risk: medium
TuHURA Biosciences, Inc. announced on October 27, 2025, that it entered into a material definitive agreement. This filing also indicates the creation of a direc
TuHURA Files S-1/A for Resale of 9.3M Shares Post-Kineta Merger — S-1/A · Sep 18, 2025 Risk: high
TuHURA Biosciences, Inc. (HURA) filed an S-1/A on September 18, 2025, primarily for the resale of up to 9,321,545 shares of common stock by selling stockholders
TuHURA Biosciences Files 8-K for Material Agreement — 8-K · Sep 11, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on September 11, 2025, reporting a material definitive agreement entered into on Sep
TuHURA's Losses Widen Amid Kineta Merger, Phase 3 Trial Launch — 10-Q · Aug 14, 2025 Risk: high
TuHURA Biosciences, Inc. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $16,188,206, up from $10,107,377 in the pr
TuHURA Biosciences Files 8-K Amendment — 8-K/A · Aug 12, 2025 Risk: low
TuHURA Biosciences, Inc./NV filed an amendment (Amendment No. 1) to its Form 8-K on August 12, 2025, reporting events as of June 30, 2025. The filing pertains t
TuHURA Biosciences Completes Asset Acquisition/Disposition — 8-K · Jun 30, 2025 Risk: medium
On June 30, 2025, TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K report detailing the completion of an acquisition or disposition o
TuHURA Biosciences Files 8-K with Corporate Updates — 8-K · Jun 27, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on June 27, 2025, reporting events as of June 23, 2025. The filing indicates amendme
TuHURA Biosciences Files 8-K: Shareholder Vote, Reg FD, Exhibits — 8-K · Jun 24, 2025 Risk: medium
TuHURA Biosciences, Inc. filed an 8-K on June 24, 2025, reporting events as of June 23, 2025. The filing indicates a submission of matters to a vote of security
TuHURA Biosciences Files 8-K — 8-K · Jun 12, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on June 12, 2025, reporting events as of June 6, 2025. The filing primarily concerns financial statements and exhibits, wi
TuHURA Biosciences Files 8-K: Material Agreement & Equity Sales — 8-K · Jun 6, 2025 Risk: medium
TuHURA Biosciences, Inc. announced on June 2, 2025, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equit
TuHURA Biosciences Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
TuHURA Biosciences, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Kintara Therapeutics, Inc., is incorporated in Nevada
TuHURA Biosciences Files 8-K/A Amendment — 8-K/A · May 7, 2025 Risk: low
TuHURA Biosciences, Inc./NV filed an amendment (8-K/A) on May 7, 2025, to a report originally dated March 7, 2025. The amendment pertains to the departure of di
TuHURA Biosciences Files 8-K on Operations — 8-K · Apr 1, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on April 1, 2025, reporting on its results of operations and financial condition. Th
TuHURA Biosciences Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
TuHURA Biosciences, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Kintara Th
TuHURA Biosciences Files 8-K — 8-K · Mar 18, 2025 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on March 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
TuHURA Biosciences Files 8-K: Board & Compensation Changes — 8-K · Mar 12, 2025 Risk: medium
TuHURA Biosciences, Inc. announced on March 7, 2025, a change in its board of directors and executive compensation arrangements. The filing also includes inform
TuHURA Biosciences Enters Material Definitive Agreement — 8-K · Feb 14, 2025 Risk: medium
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) announced on February 12, 2025, that it entered into a Material Definitive Agreement. The company
TuHURA Biosciences Changes Auditors — 8-K · Jan 3, 2025 Risk: low
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) announced on December 27, 2024, a change in its certifying accountant. The company has dismissed
TuHURA Biosciences Enters Material Definitive Agreement — 8-K · Dec 12, 2024 Risk: medium
TuHURA Biosciences, Inc. announced on December 11, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Kintara Therapeuti
TuHURA Biosciences Files 8-K — 8-K · Nov 25, 2024 Risk: low
TuHURA Biosciences, Inc. filed an 8-K on November 25, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
TuHURA Biosciences Reports Board Changes and Compensation Updates — 8-K · Nov 15, 2024 Risk: medium
TuHURA Biosciences, Inc. announced on November 12, 2024, a change in its board of directors. Specifically, the company reported the departure of directors and t
TuHURA Biosciences 10-Q: Merger, Warrants, and Preferred Stock — 10-Q · Nov 14, 2024 Risk: medium
TuHURA Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business activities, inc
Bianco Files 13D for TuHURA Biosciences — SC 13D · Oct 25, 2024 Risk: medium
James A. Bianco, President and CEO of TuHURA Biosciences, Inc., filed a Schedule 13D on October 25, 2024, indicating his beneficial ownership of the company's c
Kintara Therapeutics Reports Material Definitive Agreement & Acquisition — 8-K · Oct 21, 2024 Risk: high
Kintara Therapeutics, Inc. filed an 8-K on October 21, 2024, reporting several material events as of October 18, 2024. These include entering into a material de
Kintara Therapeutics Files 8-K — 8-K · Oct 15, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on October 15, 2024, reporting on events that occurred on October 14, 2024. The filing includes information related to R
Kintara Therapeutics Files 8-K — 8-K · Oct 8, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on October 8, 2024, reporting on results of operations, financial condition, and Regulation FD disclosures. The filing a
Kintara Therapeutics Files 2024 10-K — 10-K · Oct 7, 2024 Risk: medium
Kintara Therapeutics, Inc. filed its 10-K for the fiscal year ending June 30, 2024, reporting on its operations and financial condition. The company, formerly k
Kintara Therapeutics Files 8-K on Security Holder Vote — 8-K · Oct 4, 2024 Risk: medium
Kintara Therapeutics, Inc. filed an 8-K on October 4, 2024, to report on the submission of matters to a vote of its security holders. The filing does not provid
Kintara Therapeutics Files 8-K for Material Agreement — 8-K · Sep 25, 2024 Risk: medium
Kintara Therapeutics, Inc. filed an 8-K on September 25, 2024, reporting the entry into a material definitive agreement. The filing also includes financial stat
Kintara Therapeutics Files 8-K — 8-K · Sep 24, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 24, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, forme
Kintara Therapeutics Files 8-K with Shareholder Vote and Financial Updates — 8-K · Sep 20, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 20, 2024, reporting on the submission of matters to a vote of security holders, Regulation FD disclosures,
Kintara Therapeutics Files 8-K — 8-K · Sep 19, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 18, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Kintara Therapeutics Files 8-K — 8-K · Sep 18, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 18, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
Kintara Therapeutics Files 8-K — 8-K · Sep 11, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 11, 2024, reporting on various events. The filing includes information related to financial statements and
Kintara Therapeutics Files 8-K — 8-K · Sep 9, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 9, 2024, to report on Regulation FD disclosures and financial statements. The company, formerly known as De
Kintara Therapeutics Files 8-K — 8-K · Sep 3, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on September 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Kintara Therapeutics Files 8-K — 8-K · Aug 19, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on August 19, 2024, reporting on other events and financial statements. The company, formerly known as DelMar Pharmaceut
Kintara Therapeutics Files 8-K — 8-K · Jul 12, 2024 Risk: low
Kintara Therapeutics, Inc. filed an 8-K on July 12, 2024, reporting amendments to its articles of incorporation or bylaws and financial statements. The company,
Kintara Therapeutics to be Acquired by DelMar Pharmaceuticals — 8-K · Jul 8, 2024 Risk: medium
Kintara Therapeutics, Inc. announced on July 3, 2024, that it has entered into a definitive agreement to be acquired by DelMar Pharmaceuticals, Inc. The transac

Risk Profile

Risk Assessment: Of HURA's 48 recent filings, 3 were flagged as high-risk, 22 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Tuhura Biosciences, INC./NV's most recent 10-Q filing (Aug 14, 2025):

Revenue: N/A
Net Income: -$16,188,206
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $8,512,824
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

James Bianco
Curt P. Creely
Thomas C. Mollick
James A. Bianco

Industry Context

TuHURA Biosciences operates in the highly competitive biopharmaceutical sector, focusing on oncology and immunology. The industry is characterized by significant R&D investment, long development timelines, and stringent regulatory oversight. Key trends include the increasing focus on targeted therapies, immuno-oncology, and novel biologics like monoclonal antibodies.

Top Tags

8-K (9) · financials (9) · material-agreement (7) · filing (7) · financial-reporting (6) · corporate-governance (5) · disclosure (5) · corporate-action (5) · financial-obligation (3) · material-definitive-agreement (3)

Key Numbers

SEC File Number: 001-37823 — Identifies the company's filing history with the SEC.
IRS Employer Identification No.: 99-0360497 — Company's tax identification number.
Shares of common stock: 9,321,545 — Total shares offered for resale by selling stockholders
Last reported sale price: $2.43 — HURA common stock price on September 17, 2025
Aggregate offering amount: $12.6 million — Raised from the June 2, 2025 private placement
Warrant exercise price: $3.3125 — Per share exercise price for warrants issued in the private placement
Acquisition date: June 30, 2025 — Date of Kineta, Inc. acquisition
Warrant expiration date: December 31, 2030 — Extended expiration date for 2024 warrants
Final Tranche Offering Amount: $3.2 million — Purchased by Deferral Investors on September 5, 2025
Registration statement filing deadline: 60 calendar days — Following the Initial Closing of the private placement
Net Loss: $16.19M — Increased from $10.11M in prior year for six months ended June 30, 2025
Research and development expenses: $9.51M — Increased from $6.41M in prior year for six months ended June 30, 2025
General and administrative expenses: $7.38M — Increased from $1.81M in prior year for six months ended June 30, 2025
Cash and cash equivalents: $8.51M — Decreased from $12.66M at December 31, 2024
Goodwill: $13.55M — Recognized from Kineta acquisition as of June 30, 2025

Related Companies

THRX · TURA · TKMR · KTRA

Frequently Asked Questions

What are the latest SEC filings for Tuhura Biosciences, INC./NV (HURA)?

Tuhura Biosciences, INC./NV has 50 recent SEC filings from Jul 2024 to Apr 2026, including 40 8-K, 3 10-Q, 2 8-K/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of HURA filings?

Across 50 filings, the sentiment breakdown is: 48 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Tuhura Biosciences, INC./NV SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Tuhura Biosciences, INC./NV (HURA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Tuhura Biosciences, INC./NV?

Key financial highlights from Tuhura Biosciences, INC./NV's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for HURA?

The investment thesis for HURA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Tuhura Biosciences, INC./NV?

Key executives identified across Tuhura Biosciences, INC./NV's filings include James Bianco, Curt P. Creely, Thomas C. Mollick, James A. Bianco.

What are the main risk factors for Tuhura Biosciences, INC./NV stock?

Of HURA's 48 assessed filings, 3 were flagged high-risk, 22 medium-risk, and 23 low-risk.

What are recent predictions and forward guidance from Tuhura Biosciences, INC./NV?

Forward guidance and predictions for Tuhura Biosciences, INC./NV are extracted from SEC filings as they are enriched.